Currently, there are 167.13M common shares owned by the public and among those 142.43M shares have been available to trade.
The company’s stock has a 5-day price change of 18.87% and -1.95% over the past three months. ALLO shares are trading -21.50% year to date (YTD), with the 12-month market performance down to -0.79% lower. It has a 12-month low price of $1.99 and touched a high of $5.78 over the same period. ALLO has an average intraday trading volume of 2.12 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.48%, -5.61%, and -18.36% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Allogene Therapeutics Inc (NASDAQ: ALLO) shares accounts for 68.24% of the company’s 167.13M shares outstanding.
It has a market capitalization of $528.37M and a beta (3y monthly) value of 0.81. The earnings-per-share (ttm) stands at -$1.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.02% over the week and 9.07% over the month.
Earnings per share for the fiscal year are expected to increase by 36.48%, and -1.50% over the next financial year. EPS should shrink at an annualized rate of 1.00% over the next five years, compared to 22.18% over the past 5-year period.
Looking at the support for the ALLO, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on August 08, 2024, with the firm’s price target at $13-$11. Piper Sandler coverage for the Allogene Therapeutics Inc (ALLO) stock in a research note released on May 31, 2024 offered a Overweight rating with a price target of $11. Citigroup on their part issued Buy rating on December 08, 2023.
